
Quarterly ResultNov 4, 2026, 08:41 AM
Aprea Therapeutics Reports Q3 2026 Results; Cash Runway to Q1 2028
AI Summary
Aprea Therapeutics announced its third quarter 2026 financial results, reporting an operating loss of $5.2 million and a net loss of $4.8 million, or $(0.09) per share. The company's cash and cash equivalents increased to $37.8 million as of September 30, 2026, with an expected cash runway into the first quarter of 2028. Key operational updates include the expansion of the APR-1051 Phase 1 clinical trial to nine sites and the upcoming presentation of updated interim data at the 38th EORTC-NCI-AACR Symposium.
Key Highlights
- Aprea Therapeutics reported Q3 2026 operating loss of $5.2 million, compared to $3.1 million in Q3 2025.
- Research and development expenses increased to $3.3 million in Q3 2026 from $1.6 million in Q3 2025.
- General and administrative expenses were $1.8 million in Q3 2026, up from $1.5 million in Q3 2025.
- Net loss for Q3 2026 was $4.8 million, or $(0.09) per share, compared to a net loss of $3.0 million, or $(0.47) per share, in Q3 2025.
- Cash and cash equivalents stood at $37.8 million as of September 30, 2026, compared to $14.6 million as of December 31, 2025.
- Company expects cash runway into Q1 2028.
- Updated interim Phase 1 data for APR-1051 to be presented at the 38th EORTC-NCI-AACR Symposium on November 20, 2026.
Price Impact
More from APRE